Sustained Drug Delivery for Glaucoma

Current Data and Future Trends

Ahmad A. Aref


Curr Opin Ophthalmol. 2017;28(2):169-174. 

In This Article

Travoprost Intraocular Implants

The Travoprost Extended Release implant (ENV515; Envisia Therapeutics, Morrisville, NC, USA) is a biodegradable device fabricated using novel particle replication in nonwetting templates microparticle engineering technology. The technology allows for the production of sterile nanoparticles containing an extended release formulation of travoprost.[16] In a preclinical study of six eyes of six normotensive Beagle dogs, intracameral implantation of ENV515 resulted in a 35.3% (6.4 ± 0.6) mmHg IOP reduction from a baseline of 18.6 ± 0.2 mmHg (P < 0.001) over 8 months.[17] Implantation of the device was well tolerated with no adverse effects noted. Phase 2a human studies demonstrated an IOP reduction of 6.7 mmHg after 25 days that was comparable with a 6.6 mmHg reduction (P < 0.001) achieved with once daily dosing with travoprost ophthalmic solution administered to the fellow eye.[18] Baseline mean IOP was approximately 24 mmHg in each treatment group.

Another sustained release travoprost implant (iDose; Glaukos Corp., San Clemente CA, USA) designed for intracameral injection is currently under investigation in a phase 2 clinical trial ( Identifier: NCT02754596). The device is made of titanium and allows for continuous travoprost elution into the anterior chamber. When the device is depleted of active drug, removal and replacement with a new implant may be performed.[19]


3090D553-9492-4563-8681-AD288FA52ACE -


цена препарата вимакс